anti-pp38 Search Results


anti-pp38 antibody (thr180/tyr82  (WuXi AppTec)
90
WuXi AppTec anti-pp38 antibody (thr180/tyr82
House dust mite-induced enhancer of zeste homolog 2 (Ezh2)-mediated T-lymphocyte response was modified by p38 inhibitor. (A) Western blot analysis of Ezh2, p38, <t>pp38,</t> and Actin in Jurkat cells after adding p38 MAP kinase inhibitor, * p < 0.05, by the t -test. (B) Relative Ezh2 expression of Th1 cells to naïve CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10. The mean fluorescence intensity (MFI) of Th1 cells divided by the MFI of naïve CD4 + T cells in the same tube [(MFI of Th1 cells/MFI of naïve CD4 + T cells) × 100%] ( n = 11). (C) The mean fold change of Th1 percentage in CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10 compared to day 0 (the percentage on day 0/the percentage on day 10) ( n = 11). (D) Relative Ezh2 expression of Th2 cells to naïve CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10. The MFI of Th1 cells divided by the MFI of naïve CD4 + T cells in the same tube [(MFI of Th2 cells/MFI of naïve CD4 + T cells) × 100%] ( n = 11). (E) The mean fold change of Th2 percentage in CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10 compared to day 0 (the percentage on day 0/the percentage on day 10) ( n = 11 in each group).
Anti Pp38 Antibody (Thr180/Tyr82, supplied by WuXi AppTec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-pp38 antibody (thr180/tyr82/product/WuXi AppTec
Average 90 stars, based on 1 article reviews
anti-pp38 antibody (thr180/tyr82 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
anti-pp38  (Arigo Biolaboratories)
90
Arigo Biolaboratories anti-pp38
House dust mite-induced enhancer of zeste homolog 2 (Ezh2)-mediated T-lymphocyte response was modified by p38 inhibitor. (A) Western blot analysis of Ezh2, p38, <t>pp38,</t> and Actin in Jurkat cells after adding p38 MAP kinase inhibitor, * p < 0.05, by the t -test. (B) Relative Ezh2 expression of Th1 cells to naïve CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10. The mean fluorescence intensity (MFI) of Th1 cells divided by the MFI of naïve CD4 + T cells in the same tube [(MFI of Th1 cells/MFI of naïve CD4 + T cells) × 100%] ( n = 11). (C) The mean fold change of Th1 percentage in CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10 compared to day 0 (the percentage on day 0/the percentage on day 10) ( n = 11). (D) Relative Ezh2 expression of Th2 cells to naïve CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10. The MFI of Th1 cells divided by the MFI of naïve CD4 + T cells in the same tube [(MFI of Th2 cells/MFI of naïve CD4 + T cells) × 100%] ( n = 11). (E) The mean fold change of Th2 percentage in CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10 compared to day 0 (the percentage on day 0/the percentage on day 10) ( n = 11 in each group).
Anti Pp38, supplied by Arigo Biolaboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-pp38/product/Arigo Biolaboratories
Average 90 stars, based on 1 article reviews
anti-pp38 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
mouse anti-pp38 primary monoclonal antibody h19  (ScyTek Inc)
90
ScyTek Inc mouse anti-pp38 primary monoclonal antibody h19
House dust mite-induced enhancer of zeste homolog 2 (Ezh2)-mediated T-lymphocyte response was modified by p38 inhibitor. (A) Western blot analysis of Ezh2, p38, <t>pp38,</t> and Actin in Jurkat cells after adding p38 MAP kinase inhibitor, * p < 0.05, by the t -test. (B) Relative Ezh2 expression of Th1 cells to naïve CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10. The mean fluorescence intensity (MFI) of Th1 cells divided by the MFI of naïve CD4 + T cells in the same tube [(MFI of Th1 cells/MFI of naïve CD4 + T cells) × 100%] ( n = 11). (C) The mean fold change of Th1 percentage in CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10 compared to day 0 (the percentage on day 0/the percentage on day 10) ( n = 11). (D) Relative Ezh2 expression of Th2 cells to naïve CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10. The MFI of Th1 cells divided by the MFI of naïve CD4 + T cells in the same tube [(MFI of Th2 cells/MFI of naïve CD4 + T cells) × 100%] ( n = 11). (E) The mean fold change of Th2 percentage in CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10 compared to day 0 (the percentage on day 0/the percentage on day 10) ( n = 11 in each group).
Mouse Anti Pp38 Primary Monoclonal Antibody H19, supplied by ScyTek Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti-pp38 primary monoclonal antibody h19/product/ScyTek Inc
Average 90 stars, based on 1 article reviews
mouse anti-pp38 primary monoclonal antibody h19 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


House dust mite-induced enhancer of zeste homolog 2 (Ezh2)-mediated T-lymphocyte response was modified by p38 inhibitor. (A) Western blot analysis of Ezh2, p38, pp38, and Actin in Jurkat cells after adding p38 MAP kinase inhibitor, * p < 0.05, by the t -test. (B) Relative Ezh2 expression of Th1 cells to naïve CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10. The mean fluorescence intensity (MFI) of Th1 cells divided by the MFI of naïve CD4 + T cells in the same tube [(MFI of Th1 cells/MFI of naïve CD4 + T cells) × 100%] ( n = 11). (C) The mean fold change of Th1 percentage in CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10 compared to day 0 (the percentage on day 0/the percentage on day 10) ( n = 11). (D) Relative Ezh2 expression of Th2 cells to naïve CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10. The MFI of Th1 cells divided by the MFI of naïve CD4 + T cells in the same tube [(MFI of Th2 cells/MFI of naïve CD4 + T cells) × 100%] ( n = 11). (E) The mean fold change of Th2 percentage in CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10 compared to day 0 (the percentage on day 0/the percentage on day 10) ( n = 11 in each group).

Journal: Frontiers in Immunology

Article Title: Impact of Enhancer of Zeste Homolog 2 on T Helper Cell-Mediated Allergic Rhinitis

doi: 10.3389/fimmu.2017.00790

Figure Lengend Snippet: House dust mite-induced enhancer of zeste homolog 2 (Ezh2)-mediated T-lymphocyte response was modified by p38 inhibitor. (A) Western blot analysis of Ezh2, p38, pp38, and Actin in Jurkat cells after adding p38 MAP kinase inhibitor, * p < 0.05, by the t -test. (B) Relative Ezh2 expression of Th1 cells to naïve CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10. The mean fluorescence intensity (MFI) of Th1 cells divided by the MFI of naïve CD4 + T cells in the same tube [(MFI of Th1 cells/MFI of naïve CD4 + T cells) × 100%] ( n = 11). (C) The mean fold change of Th1 percentage in CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10 compared to day 0 (the percentage on day 0/the percentage on day 10) ( n = 11). (D) Relative Ezh2 expression of Th2 cells to naïve CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10. The MFI of Th1 cells divided by the MFI of naïve CD4 + T cells in the same tube [(MFI of Th2 cells/MFI of naïve CD4 + T cells) × 100%] ( n = 11). (E) The mean fold change of Th2 percentage in CD4 + T cells with HDM stimulation with or without p38 MAP kinase inhibitor treatment on day 10 compared to day 0 (the percentage on day 0/the percentage on day 10) ( n = 11 in each group).

Article Snippet: Antibodies used in this study described as follows: anti-p38 antibody (ABGENT, Catalog Number: AP3904a, San Diego, CA, USA); anti-pp38 antibody (Thr180/Tyr82, ABGENT, Catalog Number: AP52412, San Diego, CA, USA); anti-Ezh2 antibody (ABGENT, Catalog Number: AW5436-U400, San Diego, CA, USA); anti-IL4 antibody (PE, Clone: 8D4-8, Catalog Number: 12-7049, eBioscience, San Diego, CA, USA); anti-IFN-γ antibody (PE, Clone: 4S B3, Catalog Number: 12-7319, eBioscience, San Diego, CA, USA); anti-CD4 antibody (PERCP-CY5.5, Clone: RPA-T4, Catalog Number: 45-0049, eBioscience, San Diego, CA, USA); anti-CD45ra antibody (APC, Clone: MP4-25D2, Catalog Number: 555490, BD, San Diego, CA, USA); Donkey anti-Rat IgG (H + L) Cross-Adsorbed Secondary Antibody (DyLight ® 488, Catalog Number: SA5-10026, eBioscience, San Diego, CA, USA).

Techniques: Modification, Western Blot, Expressing, Fluorescence